Fisher & Paykel Healthcare Corporation Ltd (ASX:FPH) is expecting its net profit after tax to trend higher during the 2025 fiscal year, based on the introduction of new products and continuing changes to clinical practice. The company – whose products focus on acute and chronic respiratory care, surgery, and the treatment of obstructive sleep apnea – said its net profit after tax (NPAT) is set to be between $320 million to $370 million during FY25, a rise from the figure of between $310 million to $360 million which was indicated by full year guidance provided in May. Operating revenue was exp…